“…For AD, longitudinal changes in cerebrospinal fluid (CSF) and MRI biomarkers, such as CSF proteins (amyloid-β, amyloid precursor protein, tau protein, and other), magnetic resonance imaging brain volume and rate of atrophy, and in cognitive test scores, have been most often targeted. Several studies reported significant longitudinal changes in CSF biomarkers in AD patients, while others did not; some suggested that the shape of the association of AD biomarkers with disease severity can sometimes be nonlinear (e.g., sigmoidal or quadratic) and differ between biomarkers (Jack et al, 2013; Mattsson et al, 2012; Mouiha et al, 2012; Wildsmith et al, 2014). Other groups utilized longitudinal imaging measures to estimate temporal trajectories of cortical amyloid deposition before the onset of clinical symptoms to use them as potential predictors of progression to AD (Bilgel et al, 2015).…”